Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)
Study sponsor: NovoCure Ltd. · NVCR
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-10-16Actual
Enrollment · participants571Actual
Source updated2026-01-21Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.